Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been ...

In this Healio Video Perspective from Retina 2025, Allen C. Ho, MD, discusses the growing promise of optogenetic therapy in treating patients with retinal disease.

TOKYO -- Japanese researchers from Keio University and elsewhere announced Thursday that they have begun a clinical trial on a gene therapy to restore light sensitivity in patients with retinitis ...

A unique collaboration between electrical engineers and ophthalmologists solves clinical, computational challenges.

The restoration of differential activity is fundamental for complex retinal response to light stimulation, which allows for more natural vision." "In pre-clinical models of retinitis pigmentosa ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds were identified using a virtual screening approach.

(RTTNews) - Ocugen, Inc. (OCGN) Monday said that the European Medicines Agency's (EMA) Committee for Advanced Therapies (CAT) has provided a positive opinion for Advanced Therapy Medicinal Product ...

Motorists risk being hit with an eye-watering £1,000 fine if they fail to declare certain conditions to the DVLA ...

Chris feels contestants need to be "tough" in order to survive the stresses of 'Strictly'. The comedy star is blind due to ...

The Tokyo-based biotech firm expects RV-001 to be able to alter light sensitivity for patients with limited or no vision regardless of genotype.

Fellow-KI researchers Anders Kvanta and Fredrik Lanner have been awarded a grant of SEK 10 million from the Promobilia foundation to develop a ...